CASI Pharmaceuticals Inc  

(Public, NASDAQ:CASI)   Watch this stock  
Find more results for casi
+0.27 (9.68%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.70 - 3.18
52 week 0.91 - 4.84
Open 2.75
Vol / Avg. 526,731.00/761,132.00
Mkt cap 218.37M
P/E     -
Div/yield     -
EPS -0.12
Shares 65.07M
Beta 1.09
Inst. own 13%
Nov 14, 2017
Q3 2017 CASI Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -27.63% -56.37%
Return on average equity -39.70% -128.65%
Employees 20 -
CDP Score - -


9620 Medical Center Dr Ste 300
ROCKVILLE, MD 20850-3396
United States - Map
+1-240-8642600 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).

Officers and directors

Wei-Wu He Ph.D. Chairman of the Board
Age: 50
Bio & Compensation  - Reuters
Ken K. Ren Ph.D. Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Cynthia Wong Hu J.D. Chief Operating Officer, General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Sara B. Capitelli CPA Vice President - Finance, Principal Accounting Officer
Age: 48
Bio & Compensation  - Reuters
Rong Chen M.D., Ph.D. Chief Medical Officer
Bio & Compensation  - Reuters
Tak W. Mak Ph.D. Director
Age: 69
Bio & Compensation  - Reuters
Rajesh C. Shrotriya M.D. Director
Age: 73
Bio & Compensation  - Reuters
James Z. Huang Independent Director
Age: 50
Bio & Compensation  - Reuters
Franklin C. Salisbury Jr. Independent Director
Age: 59
Bio & Compensation  - Reuters
Y. Alexander Wu Ph.D. Independent Director
Age: 51
Bio & Compensation  - Reuters